# Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Source: https://onco.cc/trials/nct05458674/  
OnCo record `nct05458674` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tucatinib, Eribulin and Trastuzumab in advanced solid tumours, run by Criterium, Inc., active and no longer recruiting.

## Summary

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC is a phase 2 interventional study registered as NCT05458674 by Criterium, Inc., with 17 participants enrolled, started 2024-01-30 and due to reach its primary completion in 2027-06-01. Interventions recorded: Tucatinib, Eribulin and Trastuzumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05458674
- Phase: 2
- Setting: A Phase II Study of the Safety, Tolerability and Antitumor Activity of Tucatinib in Combination With Eribulin and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
- Sponsor: Criterium, Inc.
- Enrolled: 17

## Sources

- ClinicalTrials.gov NCT05458674: https://clinicaltrials.gov/study/NCT05458674

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Eribulin](https://onco.cc/drugs/eribulin/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Tucatinib](https://onco.cc/drugs/tucatinib/)

---
JSON: https://onco.cc/api/v1/entities/nct05458674.json